Antiviral dosing and efficacy for prophylaxis of cytomegalovirus disease in solid organ transplant recipients

American Journal of Health-System Pharmacy

Volumn 63, Issue SUPPL. 5, 2006, Pages

  Cochrane, Adam B ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Antivirals; Blood levels; Cytomegalovirus infections; Dosage; Drugs; Ganciclovir; Kidney failure; Metabolism; Pharmacokinetics; Toxicity; Transplantation; Valganciclovir

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; PLACEBO; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; CONFERENCE PAPER; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; HEART TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; KIDNEY TRANSPLANTATION; LEUKOPENIA; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; NEUTROPENIA; ORGAN TRANSPLANTATION; PANCREAS TRANSPLANTATION; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS INFECTION;

EID: 33749186771     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp060379     Document Type: Conference Paper

References (18)

1. Patel R, Paya CV. Infections in solid-organ transplant recipients. Clin Microbiol Rev. 1997; 10:86-124.
2. Balfour HH Jr, Chace BA, Stapleton JT et al. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med. 1989; 320:1381-7.
3. Balfour HH Jr. Antiviral drugs. N Engl J Med. 1999; 340:1255-68.
4. Cytovene package insert. Nutley, NJ: Roche Laboratories Inc.; 2000 Sep.
5. Gane E, Saliba F, Valdecasas GJ et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group. Lancet. 1997; 350:1729-33.
6. Limaye AP, Corey L, Koelle DM et al. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet. 2000; 356:645-9.
7. Jabs DA, Martin BK, Forman MS et al. Cytomegalovirus resistance to ganciclovir and clinical outcomes of patients with cytomegalovirus retinitis. Am J Ophthalmol. 2003; 135:26-34.
8. McEvoy GK, ed. Valganciclovir hydrochloride. In: AHFS drug information 2006. Bethesda, MD: American Society of Health-System Pharmacists; 2006:843-5.
9. Valcyte package insert. Nutley, NJ: Roche Laboratories Inc.; 2003 Sep.
10. Paya C, Humar A, Dominguez E et al. Valganciclovir Solid Organ Transplant Study Group. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2004; 4:611-20.
11. Pescovitz MD, Rabkin J, Merion RM et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother. 2000; 44:2811-5.
12. Gabardi S, Magee CC, Baroletti SA et al. Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis. Pharmacotherapy. 2004; 24:1323-30.
13. Gruber SA, Garnick J, Morawski K et al. Cytomegalovirus prophylaxis with valganciclovir in African-American renal allograft recipients based on donor/recipient serostatus. Clin Transplant. 2005; 19:273-8.
14. Akalin E, Sehgal V, Ames S et al. Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis. Am J Transplant. 2003; 3:731-5.
15. Wiltshire H, Hirankarn S, Farrell C et al. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients. Clin Pharmacokinet. 2005; 44:495-507.
16. Czock D, Scholle C, Rasche FM et al. Pharmacokinetics of valganciclovir and ganciclovir in renal impairment. Clin Pharmacol Ther. 2002; 72:142-50.
17. Humar A, Kumar D, Preiksaitis J et al. A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients. Am J Transplant. 2005; 5:1462-8.
18. Zamora MR, Davis RD, Leonard C et al. Management of cytomegalovirus infection in lung transplant recipients: evidence-based recommendations. Transplantation. 2005; 80(2):157-63.